Actualités

Amgen (AMGN) has moved into focus after initiating voluntary nationwide recalls of certain Corlanor and Sensipar tablet lots due to foreign substances and CGMP deviations, prompting investors to reassess drug quality and compliance risks. See our latest analysis for Amgen. Against this recall backdrop, Amgen’s recent momentum has stayed intact, with a 30 day share price return of 5.30% and a year to date share price return of 12.35%. The 1 year total shareholder return of 27.66% and 3 year...

Amgen has initiated several product recalls in the US for Sensipar (cinacalcet) and Corlanor (ivabradine). The recalls involve multiple lots, dosage strengths, and large product quantities distributed nationwide. Regulators cited current good manufacturing practice (CGMP) deviations and contamination concerns affecting certain products. The pattern of recurring recalls extends beyond a single isolated lot or event. For investors following Amgen, ticker NasdaqGS:AMGN, the scale and...